Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biopharmaceutical company, has garnered a “Moderate Buy” consensus rating from eleven ratings firms that cover the company, according to Bloomberg Ratings. Out of these firms, three research analysts have given the stock a hold rating while eight have issued a buy rating.
The average one-year price objective for Halozyme Therapeutics, as reported by brokerages that have released reports on the stock in the past year, stands at $54.27.
In recent news, CEO Helen Torley conducted a transaction involving the sale of 10,000 shares of Halozyme Therapeutics stock on Wednesday, July 26th. The shares were sold at an average price of $42.69 each, amounting to a total transaction value of $426,900.00. After this sale, Torley now holds 623,666 shares of the company’s stock with an approximate value of $26,624,301.54. This sale was disclosed through a legal filing with the Securities & Exchange Commission (SEC), and the details can be accessed on the SEC website. It is noteworthy that insiders have sold 100,000 shares of company stock valued at $4,228,900 in the last quarter alone. As things stand now, insiders own approximately 2.30% of Halozyme Therapeutics’ stock.
Halozyme Therapeutics’ most recent quarterly earnings data was announced on Tuesday, August 8th. For that period, the company revealed earnings per share (EPS) of $0.68 – surpassing analysts’ consensus estimates by$0.09 per share ($0.59). With a net margin reading at 30.21% and return on equity standing at an impressive 254.75%, it is clear that Halozyme Therapeutics performed strongly during this time frame.
Moreover,on revenue front too, the company delivered impressive results. Its revenue for the quarter amounted to $221.04 million, exceeding the consensus estimate of $201.91 million.
Research analysts foresee that Halozyme Therapeutics will post 2.48 EPS for the current fiscal year.
In conclusion, market analysts have given a “Moderate Buy” rating to Halozyme Therapeutics, with most expecting its stock price to reach an average one-year price objective of $54.27. Furthermore, recent insider activity and strong financial performance from the company in terms of earnings per share and revenue demonstrate a positive outlook for Halozyme Therapeutics in the near future.
Updated on: 05/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Robert W. Baird
Assessing the Potential of Halozyme Therapeutics: Expert Analysis and Investor Activity
Halozyme Therapeutics, a biopharmaceutical company, has been the center of attention among researchers and investors alike. As various research reports have emerged, experts offer their analysis and ratings on the company’s stock.
One notable report comes from HC Wainwright, who reissued a “buy” rating on Halozyme Therapeutics’ shares. They also set a target price of $60.00, indicating their optimism about the company’s potential for growth. This report was made public on September 8th.
StockNews.com also upgraded its rating on Halozyme Therapeutics from “hold” to “buy” in a report released on August 16th. This further suggests a positive sentiment towards the company’s stock and its future prospects.
Morgan Stanley, one of the leading investment banks, increased its target price for Halozyme Therapeutics from $60.00 to $61.00 in a research note published on August 10th. Their rating was “overweight,” indicating their belief that the stock will outperform its competitors.
TheStreet joined the chorus of positive opinions by upgrading Halozyme Therapeutics’ rating from “c+” to “b” in another research note released earlier in August. This upgrade signifies confidence in the company’s performance and stability.
However, not all reports have been glowing for Halozyme Therapeutics. The Goldman Sachs Group had previously rated the company as a “buy,” but it recently downgraded it to a “neutral” rating in July while simultaneously raising its price objective from $43.00 to $45.00.
These varying perspectives indicate how investors should exercise caution when interpreting ratings and recommendations provided by different financial institutions.
In terms of investor activity, certain large investors altered their holdings in Halozyme Therapeutics recently. Montag A & Associates Inc., for example, acquired a new position during the second quarter that is estimated to be worth around $27,000. Similarly, West Tower Group LLC purchased a new position during the same period, valued at approximately $28,000.
Bessemer Group Inc., an investment management firm, significantly increased its holdings in Halozyme Therapeutics by 366.5% during the second quarter. The firm now owns 807 shares of the company’s stock, worth approximately $29,000.
Massmutual Trust Co. FSB ADV also saw a notable increase in its holdings of Halozyme Therapeutics during the second quarter. They now own 812 shares of the company’s stock valued at around $29,000.
Finally, CWM LLC raised its holdings in Halozyme Therapeutics by 123.2% during the first quarter. The firm now owns 848 shares valued at $32,000.
It is worth noting that institutional investors own a significant portion (92.59%) of Halozyme Therapeutics’ stock, indicating their confidence in the company and its potential for growth.
On September 26th, Halozyme Therapeutics’ stock opened at $38.89 per share. Over the past year, the stock has seen a range between $29.85 and $59.46.
Halozyme Therapeutics has a debt-to-equity ratio of 9.91 and a quick ratio of 5.44 – both factors that could affect investors’ decisions regarding this particular biopharmaceutical company.
With a market capitalization of $5.13 billion and a price-to-earnings ratio of 22.74, it appears that investors have recognized Halozyme Therapeutics as an attractive investment opportunity.
However, it is essential to approach these reports with caution and conduct further research before making any investment decisions relating to Halozyme Therapeutics or any other publicly traded company for that matter